Journals / European Journal of Therapeutics / 2022 / Cilt: 28 - Sayı: 2

Clinical Characterictics and Treatments Modalities of Patients with COVID-19 İnfection During the Early Phase of the Epidemic: A Single-Center from Turkey

Pages
135–141
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Recognizing the changing treatment modalities is especially important for the management of the coronavirus disease 2019 pandemic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The emergence of coronavirus disease 2019 is a major healthcare threat.
📊
Key Findings & Data:We aimed to assist in the management of coronavirus disease 2019 infection and contribute to the literature so the hospitals may find the information about our strategies useful in their efforts to reduce the challenges they are facing in this retrospective single-center study.
💡
Conclusion & Impact:Conclusion: Recognizing the changing treatment modalities is especially important for the management of the coronavirus disease 2019 pandemic.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The emergence of coronavirus disease 2019 is a major healthcare threat. We aimed to assist in the management of coronavirus disease 2019 infection and contribute to the literature so the hospitals may find the information about our strategies useful in their efforts to reduce the challenges they are facing in this retrospective single-center study. Methods: We analyzed the data of 1260 laboratory or radiologically confirmed hospitalized cases with coronavirus disease 2019 infection to determine the clinical and epidemiological characteristics. An infectious and a chest disease physician followed all the cases and recorded demographic data, clinical signs, treatment, laboratory, and radiological findings. Results: The mean age of the patients was 51.96 years old, and 665 (52.7%) were male. The most commonly experienced symptoms at the onset of illness were cough, shortness of breath, myalgia, and fever. Most patients showed normal leucocytes counts, lymphopenia, elevated levels of C-reactive protein, procalcitonin, ferritin, lactate dehydrogenase, and creatine kinase. Conclusion: Recognizing the changing treatment modalities is especially important for the management of the coronavirus disease 2019 pandemic.

🔖

Cite This Article

BORCAK, D., GÜLLÜ, M. A., DOKUR, M., BULUT, E., ÖZALP, Ş., BALTA, M., GÜLER, T., ÇELİK, Y. (2022). Clinical Characterictics and Treatments Modalities of Patients with COVID-19 İnfection During the Early Phase of the Epidemic: A Single-Center from Turkey. European Journal of Therapeutics, Cilt: 28 - Sayı: 2, 135–141. https://ajindex.com/articles/512109

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Provenzani A, Polidori P. Covid-19 and drug therapy, what we learned. Int J Clin Pharm. 2020
  2. 42(3):833-836. [CrossRef] 2. Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. Eur J Cancer. 2020
  3. [CrossRef] 3. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Pover. 2020
  4. 9(1):29. [CrossRef] 4. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020
  5. 80(4):388-393. [CrossRef] 5. Infection guideline for COVID19/SARS COV2 (Turkish ministry of Health-2020). Available at: https://COVID19bilgi.saglik.gov.tr/depo/ rehberler/COVID-19_Rehberi.pdf. Accessed 03.01.2021. 6. Kilic AU, Kara F, Alp E, Doganay M. New threat: 2019 novel coronavirus infection and infection control perspective in Turkey. North Clin Istanb. 2020
  6. 7(2):95-98. [CrossRef] 7. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020
  7. 382(8):727-733. [CrossRef] 8. Ozma MA, Maroufi P, Khodadadi E, et al. Clinical manifestation, diagnosis, prevention and control of COVID-19 (COVID-19) during the outbreak period. Infez Med. 2020
  8. 28(2):153-165. 9. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020
  9. 108961. [CrossRef] 10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020
  10. 395(10223):497-506. [CrossRef] 11. Carotti M, Salaffi F, Sarzi-Puttini P, et al. Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. Radiol Med. 2020
  11. 125(7):636-646. [CrossRef] 12. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (COVID19). Clin Infect Dis. 2020
  12. 71(15):732-739. [CrossRef] 13. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020
  13. 30(3):269-271. [CrossRef] 14. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithrom